Knott Partners led a $43m Series D round in ILiAD Biotechnologies.

Knott Partners, a family office hedge fund, led a $43m Series D round in ILiAD Biotechnologies, a clinical stage biotech company. "We are very pleased to close the $42.8m Class D investment which will allow ILiAD to continue to progress the development of our leading next generation pertussis vaccine. From day one, the importance of inducing mucosal immunity has been central to ILiAD’s mission to achieve global eradication of disease due to B. pertussis and it’s gratifying that key investors, public health agencies and leaders in the field of infectious disease are recognizing its pivotal role," Keith Rubin, ILiAD Founder and CEO.